Ronald Rawitt
Psychiatry · New York, NYNPI 1760582555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 236 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 32.5% of the total. Reporting peaked in 2019 at $2,948 and has fallen 92.1% since, to $233 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $31.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Validus Pharmaceuticals LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$953
- Ironshore Pharmaceuticals Inc.$518
- Axsome Therapeutics, Inc.$365
- Sunovion Pharmaceuticals Inc.$364
- plus $1K from 10 others
What the payments were for
- Food & beverage$7,408100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $2,405 |
| Validus Pharmaceuticals LLC | 18 | $1,535 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $953 |
| Ironshore Pharmaceuticals Inc. | 5 | $518 |
| Axsome Therapeutics, Inc. | 11 | $365 |
| Sunovion Pharmaceuticals Inc. | 3 | $364 |
| Bausch Health US, LLC | 19 | $355 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $175 |
| Corium, LLC | 6 | $170 |
| Shire North American Group Inc | 6 | $131 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $120 |
| Alkermes, Inc. | 1 | $115 |
| Idorsia Pharmaceuticals US Inc | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Aprecia Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Equetro$1,229
- LYBALVI$461
- Jornay PM 20mg capsules (Bottle of 100)$435
- LATUDA$364
- VRAYLAR$361
- ZolpiMist$150
- ABILIFY MAINTENA$125
How this compares
$7,408 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 11 | $5,931 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $4,995 |
| Quetiapine Fumarate | 12 | $1,513 |
| Risperidone | 14 | $639 |
| Lithium Carbonate ErLithium Carbonate | 15 | $549 |
| Propranolol Hcl | 14 | $357 |
| Buspirone Hcl | 11 | $243 |
| Spironolactone | 12 | $147 |
| Aripiprazole | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.